Navegar por autor "Gómez-Reino Carnota, Juan Jesús"

Apremilast for the treatment of psoriatic arthritis

2015- Gómez-Reino Carnota, Juan Jesús; Souto Vilas, Alejandro

Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: Results from 3 phase 3, randomized, controlled trials

2014- Gómez-Reino Carnota, Juan Jesús

Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials.

2014- Gómez-Reino Carnota, Juan Jesús

Apremilast: pooled safety analysis of three phase 3, randomized, controlled trials in patients with psoriatic arthritis

2013- Gómez-Reino Carnota, Juan Jesús

Assessment of global DNA methylation in peripheral blood cell subpopulations of early rheumatoid arthritis before and after methotrexate

2015- De Andrés González, Mª Carmen; Pérez Pampín, Eva; Calaza Cabanas, Manuel; Santaclara Nores, Francisco Javier; Ortea García, Ignacio; [et al.]

Assessment of osteoarthritis candidate genes in a meta-analysis of nine genome-wide association studies

2014- Rodríguez Fontenla, Cristina; Calaza Cabanas, Manuel; Evangelou, Evangelos; Valdes, Ana M; Arden, Nigel; [et al.]

Association of a BMP5 microsatellite with knee osteoarthritis

2013- Gómez-Reino Carnota, Juan Jesús; González Martínez-Pedrayo, Antonio; Rodríguez Fontenla, Cristina

Association of a BMP5 microsatellite with knee osteoarthritis: Case-control study

2012- Rodríguez Fontenla, Cristina; Carr, Andrew; Gómez-Reino Carnota, Juan Jesús; Tsezou, Aspasia; Loughlin, John; [et al.]

Association of anti-citrullinated vimentin and anti-citrullinated α-enolase antibodies with subsets of rheumatoid arthritis.

2012-10- Montes Martínez, Ariadna; Pérez Pampín, Eva; Calaza Cabanas, Manuel; Gómez-Reino Carnota, Juan Jesús; González Martínez-Pedrayo, Antonio [et al.]

Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis.

2014-05- Montes Martínez, Ariadna; Pérez Pampín, Eva; Narváez, Javier; Cañete, Juan D; Navarro-Sarabia, Federico; [et al.]

Association of FCGR2A with response to infliximab in rheumatoid arthritis patients

2013- Gómez-Reino Carnota, Juan Jesús; González Martínez-Pedrayo, Antonio; Montes Martínez, Ariana María; Pérez Pampín, Eva

Association of systemic lupus erythematosus clinical features with European population genetic substructure.

2011- Alonso Pérez, Elisa; Suarez Gestal, Marian; Calaza Cabanas, Manuel; Witte, Torsten; Papasteriades, Chryssa; [et al.]

Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexa

2015- Gómez-Reino Carnota, Juan Jesús

Basic Aspects of Adipokines in Bone Metabolism

2015- Abella Cajigal, Vanesa; Gómez-Reino Carnota, Juan Jesús; Scotece, Morena; Gualillo ., Oreste; Pino Mínguez, Jesús; [et al.]

Beyond fat mass: Exploring the role of adipokines in rheumatic diseases

2011- Scotece, Morena; Conde Aranda, Javier; Gómez, Rodolfo; López López, Verónica; Lago Paz, Francisca; [et al.]

Bias in effect size of systemic lupus erythematosus susceptibility loci across Europe: A case-control study

2012- Alonso Pérez, Elisa; Suarez Gestal, Marian; Calaza Cabanas, Manuel; Sebastiani, Gian Domenico; Pullmann, Rudolf; [et al.]

BIOBADASER, BIOBADAMERICA, and BIOBADADERM: safety registers sharing commonalities across diseases and countries

2014- Gómez-Reino Carnota, Juan Jesús

Biologic DMARDs in patients with rheumatoid arthritis on a Spanish registry: Predictors of therapy discontinuation due to remission

2015- Gómez-Reino Carnota, Juan Jesús

Biologic monotherapy as initial treatment in patients with early rheumatoid arthritis

2012- Gómez-Reino Carnota, Juan Jesús

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement

2013- Gómez-Reino Carnota, Juan Jesús

Repositorio digital RUNA

Navegar por autor "Gómez-Reino Carnota, Juan Jesús"

Apremilast for the treatment of psoriatic arthritis ﻿

Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: Results from 3 phase 3, randomized, controlled trials ﻿

Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials. ﻿

Apremilast: pooled safety analysis of three phase 3, randomized, controlled trials in patients with psoriatic arthritis ﻿

Assessment of global DNA methylation in peripheral blood cell subpopulations of early rheumatoid arthritis before and after methotrexate ﻿

Assessment of osteoarthritis candidate genes in a meta-analysis of nine genome-wide association studies ﻿

Association of a BMP5 microsatellite with knee osteoarthritis ﻿

Association of a BMP5 microsatellite with knee osteoarthritis: Case-control study ﻿

Association of anti-citrullinated vimentin and anti-citrullinated α-enolase antibodies with subsets of rheumatoid arthritis. ﻿

Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. ﻿

Association of FCGR2A with response to infliximab in rheumatoid arthritis patients ﻿

Association of systemic lupus erythematosus clinical features with European population genetic substructure. ﻿

Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexa ﻿

Basic Aspects of Adipokines in Bone Metabolism ﻿

Beyond fat mass: Exploring the role of adipokines in rheumatic diseases ﻿

Bias in effect size of systemic lupus erythematosus susceptibility loci across Europe: A case-control study ﻿

BIOBADASER, BIOBADAMERICA, and BIOBADADERM: safety registers sharing commonalities across diseases and countries ﻿

Biologic DMARDs in patients with rheumatoid arthritis on a Spanish registry: Predictors of therapy discontinuation due to remission ﻿

Biologic monotherapy as initial treatment in patients with early rheumatoid arthritis ﻿

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement ﻿

Apremilast for the treatment of psoriatic arthritis

Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: Results from 3 phase 3, randomized, controlled trials

Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials.

Apremilast: pooled safety analysis of three phase 3, randomized, controlled trials in patients with psoriatic arthritis

Assessment of global DNA methylation in peripheral blood cell subpopulations of early rheumatoid arthritis before and after methotrexate

Assessment of osteoarthritis candidate genes in a meta-analysis of nine genome-wide association studies

Association of a BMP5 microsatellite with knee osteoarthritis

Association of a BMP5 microsatellite with knee osteoarthritis: Case-control study

Association of anti-citrullinated vimentin and anti-citrullinated α-enolase antibodies with subsets of rheumatoid arthritis.

Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis.

Association of FCGR2A with response to infliximab in rheumatoid arthritis patients

Association of systemic lupus erythematosus clinical features with European population genetic substructure.

Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexa

Basic Aspects of Adipokines in Bone Metabolism

Beyond fat mass: Exploring the role of adipokines in rheumatic diseases

Bias in effect size of systemic lupus erythematosus susceptibility loci across Europe: A case-control study

BIOBADASER, BIOBADAMERICA, and BIOBADADERM: safety registers sharing commonalities across diseases and countries

Biologic DMARDs in patients with rheumatoid arthritis on a Spanish registry: Predictors of therapy discontinuation due to remission

Biologic monotherapy as initial treatment in patients with early rheumatoid arthritis

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement